Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ef7b91bce3486d2573b69028cd8ca846 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ffa848986802842d53f43711683ed664 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a550e12e6776af25ba6990db047d66ce http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c3899a93c972ce60b070fca823112248 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_106fb742fcbf9335ae1c9b414bce8cf7 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C317-46 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C317-46 |
filingDate |
2004-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e67400ae8938ca464ebea77a71c21d98 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7ea2b8f0c4ab9e5bac60a8601707539 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a01dc4ff78fc9173149e436ca3b8d542 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_000bff588976607785fb5f36608b266a |
publicationDate |
2004-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2004103955-A1 |
titleOfInvention |
Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors |
abstract |
The invention encompasses novel compounds of Formula (I), which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions and methods for treating cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula (I). The above compounds may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while also reducing the risk of thrombotic cardiovascular events. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005070874-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7622501-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7622502-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005070883-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2148665-A1 |
priorityDate |
2003-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |